U20. In Vivo Experimental Platform
- Scientific Director: Prof. Simó Schwartz Jr. firstname.lastname@example.org
- Scientific Coordinator: Dr. Ibane Abasolo email@example.com
- Entities: Vall d’Hebron Institut de Recerca (VHIR)
- Address: Passeig Vall d’Hebron , 119-129, 08035, Barcelona, Spain
- Phone: +34 934 893 000 ext 3375
- Web: CIBBIM-Nanomedicine & VHIR/FVPR
Located at the Valld’Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. All three sections are included within the Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine.
This unit is leadedby Dr. Ibane Abasolo (Head of FVPR) and supervised by the directorof CIBBIM-Nanomedicine, Dr. Simó Schwartz Jr. Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Although in Spain there are other institutions with similar equipment, this is the only case in which imaging services can be combined with specifically devoted animal models.
- U20-S02. Animal models in oncology (Remote) OUTSTANDING
- U20-S03. In vivo Experimental consultancy (Remote) OUTSTANDING
- U20-S04. In vivo Efficay Assays of drugs, nanomedicines, biomaterials and others (Remote) OUTSTANDING
- U20-S05. In vivo Toxicology (Onsite&Remote) OUTSTANDING
- U20-S06 In vivo ADME and biodistribution assays (Remote) OUTSTANDING
- U20-S07 In vivo PK/PD assays (Remote) OUTSTANDING
- U20-S08 Immunotoxicity assays (On-site&Remote) OUTSTANDING
- U20-S09 X-ray imaging in vitro and in vivo (Remote) OUTSTANDING
- U20-S10 Ultrasound imaging in vivo (Remote) OUTSTANDING
- U20-S11 Histological porcessing, section and staining (Remote) OUTSTANDING
- U20-S12 Inmunihistochemistry on histological samples (Remote) OUTSTANDING
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
|Title||Fundin: Organism||Call: Funding source||Role|
|ICTS-2017-10-CIBER-2||Acquisition and istallation of infrastrucuture to complemnt Unis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivo Experiment||Ministerio de Economía, Industria y Competitividad (MINECO)||Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt)||Coordinator|
|GA: 720942||SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry||Unión Europea (Comisión Europea)||H2020-NMBP-2016-2017||Coordinator|
|SAF2017-90810-REDI||Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II||Agencia Estatal de Investigación (AEI)||Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017||Coordinator|
|Ref||Title||Funding Organism||Unit Role|
|RTC-2014-2207-1||TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases||MINECO||Participant|
- Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.
- Pesarrodona M., Fernandez Y., Foradada L., Sanchez-Chardi A., Conchillo-Sole O., Unzueta U. et al. Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication. 2016;8(2):-.
- Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
- Cespedes M.V., Fernandez Y., Unzueta U., Mendoza R., Seras-Franzoso J., Sanchez-Chardi A. et al. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports. 2016;6:-.
Last week took place in Braga, Portugal, the Nanomed Europe Conference, NME19, a new and unique conference born from the merge of the 14th annual event of the ETPN & the European scientific conference ENM (after London 2017 & Grenoble 2015), bringing together scientists, technology providers, entrepreneurs, industry and clinicians, all of them developing great medical applications of Nanotechnologies and emerging MedTech. The event is been co-organized this year by the ETPN and INL. Simó Schwartz, Scientific Director of NANBIOSIS U20, was one of the selected speakers and gave a lecture about “Preclinical development of magnetic nanoparticles for the treatment of pancreatic cancer” Two posters mentioning t[...]
During the days 22-24 of May is taking place in Madrid the 3rd Workshop of introduction to the preclinical molecular image and its application to biomedical research,. The wokshop has been organized by the Health Research Institute of the Gregorio Marañón Hospital, the Complutense University of Madrid and the Madrilenian Network of nanomedicine in molecular imaging (RENIM-CM). The program counts with theoretical sessions of introduction to the physical foundations of each one of the modalities of image and its applications to preclinical biomedical research, as well as practical demonstrations of said image techniques. Ibane Abásolo, Scientific Coordinator of Unit 20[...]
Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge the efforts made by scientific women who struggle every day to contribut[...]
The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths. Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%. The only way to understand cancer and,[...]
Last November 19, Vall d’Hebron held a seminar on Lysosomal Rare Disorders: Focus on Fabry Disease as part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European Commission, the Center for Biomedical Research Network on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and the CIBBIM-Nanomedicine at Vall d Hebron Research Institute (VHIR) through the Smart-4-Fabry projec In the second plenary session, moderated by Nora Ventosa and Simó Schwartz, Scientific Directors of NANBIOSIS units 6 and 20 and devoted to New therapeutic strategies for lysosomal disorders, the speakers presented their findings regarding biomarkers, genetic variants and treatment protocols.[...]
NANBIOSIS, U20. In Vivo Experimental Platform, led by Dr. Simó Schwartz and Dr. Ibane Ibasolo, has been recently updated and improved as a result of its participation in the project FICTS1420-20, selected by the MICINN for co-financing by the FEDER Program in ICTS 2014-2020. These update and improvement include: DLS meassurement system, a fluorimeter and a waterbath for specific activity assays. The fine characterization of the size and size distribution of nanoparticles is essential for the right understanding of their in vivo behavior. The incorporation of this service to the U20 allows the determination of the drug/fluorophore loading/activity of the drug delivery systemistered in vivo, a good quality[...]
Ibane Abásolo, Scientific Coordinator of NANBIOSIS U20, explains in this video the studies of biodistribution, safety and efficacy of nanotechnological systems of pharmacological liberation that are developed in this unit and , overall, their expertise and differentiation in the sector in the evaluation of nanosystems (with certification ISO 901-2015)[...]
Yesterday took place in Barcelona, at Barcelona School of Management, Universitat Pompeu Fabra, a meeting of resarch groups and units of NANBIOSIS and CIBER-BBN and companies in the third B2B Forum organized by NANBIOSIS, in this case together with NANOMED SPAIN. Thirteen companies and twelve groups from CIBER-BBN and CCMIJU (ten of them coordinating NANBIOSIS units) got together to explain, through short presentations of ten minutes, those lines of their work aimed at finding synergies and potential collaborations in the area of Nanomedicine apllications in drug delivery and targeting. There was also a talk by a representative of CDTI (Spanis[...]